Company Encyclopedia
View More
name
Tarsus Pharmaceuticals
TARS.US
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention.
4.514 T
TARS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking16/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-28.35%E
    • Profit Margin-22.17%E
    • Gross Margin79.28%A
  • Growth ScoreA
    • Revenue YoY182.44%A
    • Net Profit YoY39.59%B
    • Total Assets YoY42.06%A
    • Net Assets YoY41.10%A
  • Cash ScoreC
    • Cash Flow Margin-451.10%E
    • OCF YoY182.44%A
  • Operating ScoreB
    • Turnover0.8B
  • Debt ScoreB
    • Gearing Ratio37.32%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tarsus Pharmaceuticals to Join BTIG Annual Ophthalmology Investor Conference

    Tarsus Pharmaceuticals Inc. will participate in a fireside chat at the BTIG 5th Annual Ophthalmology Day on December 1st. The event will be webcast live and available for replay on the Tarsus website. This information was originally published by Tarsus Pharmaceuticals via GlobeNewswire.

    Reuters·
    US
    TARS
    -0.06%
    Reuters·
    US
    TARS
    -0.06%

    Mizuho Begins Coverage on Tarsus Pharmaceuticals (NASDAQ:TARS)

    Mizuho initiated coverage on Tarsus Pharmaceuticals with an "outperform" rating and a $100 target price, suggesting a 29.68% upside. Other analysts have varied ratings, with an average target price of $74.14. Tarsus opened at $77.11, with a market cap of $3.27 billion. Recent insider sales and institutional trading activities are noted. Tarsus reported better-than-expected earnings, with a negative net margin and return on equity. Analysts predict a -3.17 EPS for the fiscal year.

    Market Beat·
    US
    TARS
    -0.06%
    Market Beat·
    US
    TARS
    -0.06%

    Tarsus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

    Tarsus Pharmaceuticals' earnings call highlighted strong growth driven by the successful launch of XDEMVY, generating $119 million in revenue. The company reported $118.7 million in Q3 revenue, with forecasts of $140-$145 million for Q4. Despite challenges with Medicare discounts and rising operational costs, Tarsus is expanding its therapeutic portfolio and anticipates a Phase II trial for TP-04. The company's marketing efforts have significantly increased brand awareness. Overall, Tarsus remains optimistic about its growth trajectory despite ongoing challenges.

    Tip Ranks·
    US
    TARS
    -0.06%
    Tip Ranks·
    US
    TARS
    -0.06%

    Tarsus Pharmaceuticals to Join Guggenheim Healthcare Innovation Conference

    Tarsus Pharmaceuticals Inc. will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 11. The event will be available via live webcast on the Tarsus website, with replays accessible within 48 hours.

    Reuters·
    US
    TARS
    -0.06%
    Reuters·
    US
    TARS
    -0.06%

    Tarsus Pharmaceuticals Reports Q3 XDEMVY Sales Surge to $119 Million

    Tarsus Pharmaceuticals Inc. reported a significant increase in Q3 2025 financial results, with XDEMVY® net sales reaching $119 million, a 147% year-over-year rise. Year-to-date sales totaled $299.7 million, driven by 266,000 bottles delivered. The company also saw a 30% increase in weekly prescribers. As of September 30, 2025, Tarsus had $401.8 million in cash and equivalents. Cost of sales rose to $19.8 million due to higher manufacturing costs. The company plans to expand its pipeline targeting ocular rosacea.

    Reuters·
    US
    TARS
    -0.06%
    Reuters·
    US
    TARS
    -0.06%
    © 2025 Longbridge｜Disclaimer